Chapter 146
Purpura Fulminans
Michael Levin, Brian Eley, Saul N. Faust,
Saul N. Faust
University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
Search for more papers by this authorMichael Levin, Brian Eley, Saul N. Faust,
Saul N. Faust
University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
Search for more papers by this authorBook Editor(s):Peter Hoeger,
Veronica Kinsler,
Albert Yan,
John Harper,
Arnold Oranje,
Christine Bodemer,
Margarita Larralde,
David Luk, Vibhu Mendiratta,
Diana Purvis,
Peter Hoeger
Search for more papers by this authorVeronica Kinsler
Search for more papers by this authorAlbert Yan
Search for more papers by this authorJohn Harper
Search for more papers by this authorArnold Oranje
Search for more papers by this authorChristine Bodemer
Search for more papers by this authorMargarita Larralde
Search for more papers by this authorVibhu Mendiratta
Search for more papers by this authorDiana Purvis
Search for more papers by this authorSummary
Purpura fulminans is a very rare complication of infection, autoimmunity, drugs or snake bite. Identification of the specific cause in individual cases is important because specific treatment options are available based on the underlying pathophysiology. In the emergency situation, supportive medical and surgical treatments are similar regardless of cause.
References
- Hjort PF, Rapaport SI, Jorgensen L. Purpura fulminans: report of a case successfully treated with heparin and hydrocortisone: review of 50 cases from the literature. Scand J Haematol 1964; 1: 169–92.
- Adcock DM, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminans. Semin Thromb Hemost 1990; 16: 283–92.
- Henoch E. Ueber Purpura fulminans. Berl Klin Wochenschr 1887: 8–10.
- Francis RB, Jr. Acquired purpura fulminans. Semin Thromb Hemost 1990; 16: 310–25.
- Dodd HJ, Sarkany I, O'Shaughnessy D. Widespread cutaneous necrosis associated with the lupus anticoagulant. Clin Exp Dermatol 1985; 10: 581–6.
- Adcock DM, Brozna J, Marlar RA. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis. Semin Thromb Hemost 1990; 16: 333–40.
- Branson HE, Katz J. A structured approach to the management of purpura fulminans. J Natl Med Assoc 1983; 75: 821–5.
- Hatterley PG. Purpura fulminans: complete recovery with intravenously administered heparin. Am J Dis Child 1970; 120: 467–71.
- Daeschner CW, 3rd, Carpentieri U. Purpura fulminans. Tex Med 1981; 77: 62–4.
- Dudgeon DL, Kellogg DR, Gilchrist GS et al. Purpura fulminans. Arch Surg 1971; 103: 351–8.
- Nadel S, Levin M, Habibi P. Treatment of meningococcal disease in childhood. In: K Cartwright (ed.) Meningococcal Disease. Chichester: John Wiley & Sons Ltd, 1995: 207–43.
- Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16: 299–309.
- Dreyfus M, Magny JF, Bridey F et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Eng J Med 1991; 325: 1565–8.
- Fourrier F, Lestavel P, Chopin C et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Int Care Med 1990; 16: 121–4.
- Powars D, Larsen R, Johnson J et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993; 17: 254–61.
- Levin M, Eley BS, Louis J et al. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatrics 1995; 127: 355–63.
- Sotto MN, Langer B, Hoshino-Shimizu S et al. Pathogenesis of cutaneous lesions in acute meningococcemia in humans: light, immunofluorescent, and electron microscopic studies of skin biopsy specimens. J Infect Dis 1976; 133: 506–14.
- Faust SN, Levin M, Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408–16.
- Shennan AT. Purpura necrotica as a complication of ventriculoatrial shunts in hydrocephalus. Arch Dis Child 1972; 47: 821–3.
- Issacman SH, Heroman WM, Lightsey AL. Purpura fulminans following late-onset group B beta-hemolytic streptococcal sepsis. Am J Dis Child 1984; 138: 915–6.
- Canale ST, Ikard ST. The orthopaedic implications of purpura fulminans. J Bone Joint Surg Am 1984; 66: 764–9.
- Johansen K, Hansen ST, Jr. Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis. Am J Surg 1993; 165: 642–5.
- Santamaria JP, Kenney S, Stiles AD. Purpura fulminans associated with Haemophilus influenzae type B infection. N C Med J 1985; 46: 516–7.
- Brazilian Purpuric Fever Study Group. Haemophilus aegyptius bacteraemia in Brazilian purpuric fever. Brazilian Purpuric Fever Study Group. Lancet 1987; 2(8562): 761–3.
- Schafer J, Ambrus M, Morvay L et al. [Repeated attack of purpura fulminans associated with Pseudomonas pyocyanea septicemia]. Orv Hetil 1972; 113: 1608–11.
- Toews WH, Bass JW. Skin manifestations of meningococcal infection; an immediate indicator of prognosis. Am J Dis Child 1974; 127: 173–6.
- Wong VK, Hitchcock W, Mason WH. Meningococcal infections in children: a review of 100 cases. Pediatr Infect Dis J 1989; 8: 224–7.
- Pollard AJ, Britto J, Nadel S et al. Emergency management of meningococcal disease. Arch Dis Child 1999; 80: 290–6.
- Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child 2003; 88: 601–7.
- Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child 2003; 88: 608–14.
- Booy R, Habibi P, Nadel S et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85: 386–90.
- Thorburn K, Baines P, Thomson A et al. Mortality in severe meningococcal disease. Arch Dis Child 2001; 85: 382–5.
- Faust SN, Heyderman RS, Levin M. Disseminated intravascular coagulation and purpura fulminans secondary to infection. Baillieres Best Pract Res Clin Haematol 2000; 13: 179–97.
- Coureuil M, Bourdoulous S, Marullo S et al. Invasive meningococcal disease: a disease of the endothelial cells. Trends Mol Med 2014; 20: 571–8.
- Lecuyer H, Borgel D, Nassif X et al. Pathogenesis of meningococcal purpura fulminans. Pathog Dis 2017; 75.
- Dixon GL, Heyderman RS, Kotovicz K et al. Endothelial adhesion molecule expression and its inhibition by recombinant bactericidal/permeability-increasing protein are influenced by the capsulation and lipooligosaccharide structure of Neisseria meningitidis. Infect Immun 1999; 67: 5626–33.
- Heyderman RS, Klein NJ, Daramola OA et al. Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium. Microb Pathog 1997; 22: 265–74.
- Klein NJ, Shennan GI, Heyderman RS et al. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102: 821–32.
- Heyderman RS, Klein NJ, Shennan GI et al. Deficiency of prostacyclin production in meningococcal shock. Arch Dis Child 1991; 66: 1296–9.
- Heyderman RS, Klein NJ, Shennan GI et al. Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb Res 1992; 67: 677–85.
- Eling M, Stephens AC, Oragui EE et al. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost 2001; 85: 240–4.
- Esmon CT, Taylor FB, Jr, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66: 160–5.
- Leclerc F, Hazelzet J, Jude B et al. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 1992; 18: 202–5.
- Brandtzaeg P, Joo GB, Brusletto B et al. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271–8.
- Kornelisse RF, Hazelzet JA, Savelkoul HF et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173: 1148–56.
- Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354(9178): 561–3.
- Hermans PW, Hibberd ML, Booy R et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354(9178): 556–60.
- Brandtzaeg P, Sandset PM, Joo GB et al. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55: 459–70.
- Nguyen P, Reynaud J, Pouzol P et al. Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 1994; 153: 646–9.
- Phillips WG, Marsden JR, Hill FG. Purpura fulminans due to protein S deficiency following chickenpox. Br J Dermatol 1992; 127: 30–2.
- D'Angelo A, Della Valle P, Crippa L et al. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993; 328: 1753–7.
- Manco-Johnson MJ, Nuss R, Key N et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996; 128: 319–23.
- Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 1989; 114: 528–34.
- Millar DS, Allgrove J, Rodeck C et al. A homozygous deletion/insertion mutation in the protein C (PROC) gene causing neonatal Purpura fulminans: prenatal diagnosis in an at-risk pregnancy. Blood Coagul Fibrinol 1994; 5: 647–9.
- Marlar RA, Sills RH, Groncy PK et al. Protein C survival during replacement therapy in homozygous protein C deficiency. Am J Hematol 1992; 41: 24–31.
- McGehee WG, Klotz TA, Epstein DJ et al. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101: 59–60.
- Teepe RG, Broekmans AW, Vermeer BJ et al. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122: 1408–12.
- Friedman KD, Marlar RA, Houston JG et al. Warfarin induced skin necrosis in a patient with protein S deficiency. Blood 1986; 68(Supp; 1):333a (abstract).
- Michiels JJ, Bertina RM. Thrombo-haemorrhagic skin necrosis due to rapid development of severe vitamin K deficiency associated with cholestasis. Thromb Haemost 1987: 413 (abstract).
- Kant KS, Glueck HI, Coots MC et al. Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 19: 264–71.
- Gordon BG, Haire WD, Patton DF et al. Thrombotic complications of BMT: association with protein C deficiency. Bone Marrow Transplant 1993; 11: 61–5.
- Jindal BK, Martin MF, Gayner A. Gangrene developing after minor surgery in a patient with undiagnosed systemic lupus erythematosus and lupus anticoagulant. Ann Rheum Dis 1983; 42: 347–9.
- Kisker CT, Glueck H, Kauder E. Anaphylactoid purpura progressing to gangrene and its treatment with heparin. J Pediatr 1968; 73: 748–51.
- Stephens CJ. The antiphospholipid syndrome. Clinical correlations, cutaneous features, mechanism of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolipin antibodies. Br J Dermatol 1991; 125: 199–210.
- Key NS. Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid antibody syndrome. J Lab Clin Med 1995; 125: 16–7.
- Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508–12.
- Khamashta MA, Cuadrado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993–7.
- White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy: including six cases of heparin-induced skin necrosis. Ann Surg 1979; 190: 595–608.
- Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–5.
- Luttengs WF. Skin necrosis in a patient with thrombotic thrombocytopenic purpura. Ann Intern Med 1957: 1207–13.
- Rietschel RL, Lewis CW, Simmons RA et al. Skin lesions in paroxysmal nocturnal hemoglobinuria. Arch Dermatol 1978; 114: 560–3.
- Levin M, Quint PA, Goldstein B et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000; 356(9234): 961–7.
- Genoff MC, Hoffer MM, Achauer B et al. Extremity amputations in meningococcemia-induced purpura fulminans. Plast Reconstr Surg 1992; 89: 878–81.
- Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis 1998; 26: 1159–64.
- Huang DB, Price M, Pokorny J et al. Reconstructive surgery in children after meningococcal purpura fulminans. J Pediatr Surg 1999; 34: 595–601.
- Hunt DM. The orthopaedic management of purpura fulminans in meningococcal disease in children. Care Critical Ill 2001; 17: 118–20.
- Buysse CM, Oranje AP, Zuidema E et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child 2009; 94: 381–6.
- Muller FM, Ehrenthal W, Hafner G et al. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr 1996; 155: 20–5.
- Dreyfus M, Masterson M, David M et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995; 21: 371–81.
- Lehner PJ, Davies KA, Walport MJ et al. Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet. 1992; 340(8832): 1379–81.
- Busund R, Straume B, Revhaug A. Fatal course in severe meningococcemia: clinical predictors and effect of transfusion therapy. Crit Care Med 1993; 21: 1699–705.
- de Jonge E, Levi M, Stoutenbeek CP et al. Current drug treatment strategies for disseminated intravascular coagulation. Drugs 1998; 55: 767–77.
- Kuppermann N, Inkelis SH, Saladino R. The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J 1994; 13: 867–73.
- Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60: 284–7.
- Ockelford P. Heparin 1986. Indications and effective use. Drugs 1986; 31: 81–92.
- White B, Livingstone W, Murphy C et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719–24.
- De Kleijn ED, De Groot R, Hack CE et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31: 1839–47.
- Balk R, Emerson T, Fourrier F et al. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost 1998; 24: 183–94.
- Bernard G, Artigas A, Dellinger P et al. Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis. Crit Care Med 2001; 29(7 Suppl): S75–7.
- Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709.
- Poole D, Bertolini G, Garattini S Withdrawal of ‘Xigris’ from the market: old and new lessons. J Epidemiol Commun Health 2012; 66: 571–2.
- Giudici D, Baudo F, Palareti G et al. Antithrombin replacement in patients with sepsis and septic shock. Haematologica 1999; 84: 452–60.
- Emerson TE, Jr. Antithrombin III replacement in animal models of acquired antithrombin III deficiency. Blood Coagul Fibrinolysis 1994; 5 Suppl 1: S37–45;discussion S59–64.
- Taylor FB Jr, Emerson TE Jr, Jordan R et al. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26: 227–35.
- Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869–78.
- Zenz W, Muntean W, Gallistl S et al. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995; 96: 44–8.
- Nadel S, De Munter C, Britto J et al. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans [letter; comment]. Crit Care Med 1998; 26: 971–2; discussion 2–3.
- Zenz W, Zoehrer B, Levin M et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med 2004; 32: 1777–80.
- Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161: 71–7.
- Dix D, Andrew M, Marzinotto V et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136: 439–45.
- Arevalo JM, Lorente JA, Fonseca R. Surgical treatment of extensive skin necrosis secondary to purpura fulminans in a patient with meningococcal sepsis. Burns 1998; 24: 272–4.
- Harris NJ, Gosh M. Skin and extremity loss in meningococcal septicaemia treated in a burn unit. Burns 1994; 20: 471–2.
- Hudson DA, Goddard EA, Millar KN. The management of skin infarction after meningococcal septicaemia in children. Br J Plast Surg 1993; 46: 243–6.
- Fitton AR, Dickson WA, Shortland G et al. Peripheral gangrene associated with fulminating meningococcal septicaemia. Is early escharotomy indicated? J Hand Surg (Br) 1997; 22: 408–10.
- Morris ME, Maijub JG, Walker SK et al. Meningococcal sepsis and purpura fulminans: the surgical perspective. Postgrad Med J 2013; 89(1052): 340–5.
